Tetraphase Pharmaceuticals Overview
- Founded
- 2006

- Status
- Acquired/Merged
- Employees
- 67

- Latest Deal Type
- M&A
- Latest Deal Amount
- $59M

Tetraphase Pharmaceuticals General Information
Description
Tetraphase Pharmaceuticals Inc is a biopharmaceutical company using its proprietary chemistry technology to create, develop and commercialize novel tetracyclines for serious and life-threatening conditions, including bacterial infections caused by multidrug-resistant, or MDR, bacteria. The company has developed its product, Xerava (eravacycline), a fully synthetic fluorocycline, as an intravenous, or IV antibiotic for use as a first-line empiric monotherapy for the treatment of MDR infections, including MDR Gram-negative infections, such as those found in complicated intra-abdominal infections, or cIAI.
Contact Information
(Operating Subsidiary)
- 480 Arsenal Way
- Suite 100
- Watertown, MA 02472
- United States
Tetraphase Pharmaceuticals Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
11. Merger/Acquisition | 28-Jul-2020 | $59M | 00000 | 0000 | Completed | Generating Revenue/Not Profitable |
10. Merger/Acquisition | 16-Mar-2020 | 000.00 | 000.00 | Cancelled | Generating Revenue/Not Profitable | |
9. PIPE | 22-Jan-2020 | 000.00 | 00000 | Completed | Generating Revenue | |
8. Secondary Transaction - Open Market | 01-Mar-2018 | 00000 | Completed | Generating Revenue | ||
7. 2PO | 27-Jul-2017 | 0000 | 00000 | Completed | Generating Revenue | |
6. 2PO | 11-Mar-2015 | 00000 | 00000 | 00.000 | Completed | Generating Revenue |
5. Secondary Transaction - Open Market | 01-Mar-2015 | 00000 | Completed | Generating Revenue | ||
4. IPO | 20-Mar-2013 | 0000 | 00000 | 00000 | Completed | Generating Revenue |
3. Later Stage VC (Series C) | 01-Jun-2010 | $45.1M | $70.1M | 00000 | Completed | Generating Revenue |
2. Early Stage VC (Series B) | 06-Oct-2009 | $10.1M | $25M | 000.00 | Completed | Startup |
Tetraphase Pharmaceuticals Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series C | 000,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 | |
Series B | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 | |
Series A2 | 13,095,646 | $0.001000 | $0.69 | $0.69 | 1x | $0.18 | 16.31% | |
Series A1 | 10,072,000 | $0.001000 | $0.6 | $0.6 | 1x | $0.18 | 10.9% |
Tetraphase Pharmaceuticals Comparisons
Industry
00000000
0000000
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialTetraphase Pharmaceuticals Competitors (22)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Scynexis | Formerly VC-backed | Jersey City, NJ | 00 | 00000 | 000000000 | 00000 |
0000000 0000000000 | Formerly VC-backed | Waltham, MA | 00 | 00000 | 000000000 | 00000 |
0000000 0000000000 | Formerly VC-backed | Cambridge, MA | 0000 | 00.00 | 00000000000 | 00.00 |
000000000 00000000 | Formerly VC-backed | Boston, MA | 00 | 00000 | 000000000 | 00000 |
000000000 | Venture Capital-Backed | Basel, Switzerland | 00 | 000.00 | 00000000000 | 000.00 |
Tetraphase Pharmaceuticals Executive Team (13)
Tetraphase Pharmaceuticals Board Members (13)
Name | Representing | Role | Since |
---|---|---|---|
John Freund MD | Self | Board Member | 000 0000 |
Patrick Gage Ph.D | Self | Chairman of the Board of Director | 000 0000 |
Tetraphase Pharmaceuticals Signals
Growth Rate

Growth

Size Multiple


Key Data Points
Twitter Followers
5.5k

Similarweb Unique Visitors
15.0K

Majestic Referring Domains
314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialTetraphase Pharmaceuticals Former Investors (10)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Armistice Capital | Hedge Fund | Minority | 000 0000 | 000000 0 | |
BB Biotech | Asset Manager | Minority | 000 0000 | 000000 0 | |
Bay City Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
Excel Venture Management | Venture Capital | Minority | 000 0000 | 000000 0 | |
F-Prime Capital | Venture Capital | Minority | 000 0000 | 000000 0 |